METABOLISM OF BIG ENDOTHELIN-1-(1-38) AND ENDOTHELIN-1-(22-38) IN THE HUMAN CIRCULATION IN RELATION TO PRODUCTION OF ENDOTHELIN-1-(1-21)

被引:89
作者
HEMSEN, A [1 ]
AHLBORG, G [1 ]
OTTOSSONSEEBERGER, A [1 ]
LUNDBERG, JM [1 ]
机构
[1] HUDDINGE UNIV HOSP,DEPT CLIN PHYSIOL & NEPHROL,STOCKHOLM,SWEDEN
关键词
RADIOIMMUNOASSAY; ENDOTHELIN CONVERTING ENZYME; PLASMA CLEARANCE; PLASMA HALF-LIFE;
D O I
10.1016/0167-0115(94)00119-I
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Healthy male volunteers received intravenous infusions of Big endothelin (ET)-1 (1-38) or Big ET-1 (22-38). Blood samples were drawn from catheters in the brachial and pulmonary arteries and the hepatic, renal, jugular and deep forearm veins. The in vivo half-lives of circulating plasma Big ET-1 (1-38) were 6.61+/-0.3 min for the initial phase and 23 +/- 1.4 min for the late phase. The corresponding half-lives of Big ET-1 (22-38) were considerably shorter, being 0.9 +/- 0.03 min (P<0.01) and 3.1 +/- 0.4 min (P<0.01), respectively. This was concordant with the efficient regional clearance of Big ET-1 (22-38), which was most prominent in the forearm muscle (51 +/- 3%), liver (44 +/- 5%) and kidney (43 +/- 3 %) and less pronounced in the lungs (14 +/- 2%) and brain (22 +/- 5%). Significant fractional extraction of Big ET-1 (1-38) was only found for the liver (30 +/- 2%) and kidney (44 +/- 3 %). During the infusion of Big ET-1 (1-38) a positive veno-arterial gradient of ET-1-LI was noted only for the kidney, indicating production of ET-1. Tn conclusion, whereas Big ET-I (22-38)is eliminated in skeletal muscle, splanchnic, renal, pulmonary and cerebral vascular beds, Big ET-1 (1-38) is extracted mainly in the renal and splanchnic vasculature. Furthermore, plasma half-life of Big ET-1 (1-38) is much longer than that of both ET-1 and Big ET-1 (22-38) in man. Thus, for investigation of the secretory activity of the ET-1-system measurements of Big ET-1 (1-38) levels may be a better approach.
引用
收藏
页码:287 / 297
页数:11
相关论文
共 17 条
  • [1] AHLBORG E, 1994, CARDIOVASC RES, V28, P1559
  • [2] IMMUNOREACTIVE ENDOTHELIN IN HUMAN-PLASMA - MARKED ELEVATIONS IN PATIENTS IN CARDIOGENIC-SHOCK
    CERNACEK, P
    STEWART, DJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) : 562 - 567
  • [3] CONCOMITANT SECRETION OF BIG ENDOTHELIN AND ITS C-TERMINAL FRAGMENT FROM HUMAN AND BOVINE ENDOTHELIAL-CELLS
    EMORI, T
    HIRATA, Y
    OHTA, K
    SHICHIRI, M
    SHIMOKADO, K
    MARUMO, F
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (01) : 217 - 223
  • [4] ANTIBODIES TO BRADYKININ + ANGIOTENSIN - USE OF CARBODIIMIDES IN IMMUNOLOGY
    GOODFRIEND, TL
    LEVINE, L
    FASMAN, GD
    [J]. SCIENCE, 1964, 144 (362) : 1344 - &
  • [5] PRESENCE OF ENDOTHELIN-1 AND ENDOTHELIN-3 IN PERIPHERAL-TISSUES AND CENTRAL-NERVOUS-SYSTEM OF THE PIG
    HEMSEN, A
    LUNDBERG, JM
    [J]. REGULATORY PEPTIDES, 1991, 36 (01) : 71 - 83
  • [6] HEMSEN A, 1991, ACTA PHYSL SCAND, V141, P319
  • [7] LOFFLER BM, 1992, BIOCHEM INT, V27, P755
  • [8] PHOSPHORAMIDON, A METALLOPROTEINASE INHIBITOR, SUPPRESSES THE HYPERTENSIVE EFFECT OF BIG ENDOTHELIN-1
    MATSUMURA, Y
    HISAKI, K
    TAKAOKA, M
    MORIMOTO, S
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 185 (01) : 103 - 106
  • [9] INCREASED PLASMA-CONCENTRATIONS OF ENDOTHELIN-1 AND BIG ENDOTHELIN-1 IN ACUTE MYOCARDIAL-INFARCTION
    MIYAUCHI, T
    YANAGISAWA, M
    TOMIZAWA, T
    SUGISHITA, Y
    SUZUKI, N
    FUJINO, M
    AIISAKA, R
    GOTO, K
    MASAKI, T
    [J]. LANCET, 1989, 2 (8653) : 53 - 54
  • [10] MODIN A, 1991, LIFE SCI, V49, P1691